文献速递创伤骨科骨质疏松与代谢性骨病

慢性肾脏病合并髋部骨折患者新发脆性骨折风险:英国人群队列研究

The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK.
PubMed 文献 · Osteoporos Int · 2020-04-07

该英国人群队列研究评估首次髋部骨折后,CKD G3-G5期与eGFR>60 ml/min患者相比新发非髋部骨折或脆性骨折的风险。结果显示CKD G3-G5与任何后续非髋部骨折风险降低相关(HR 0.90),但与主要非髋部脆性骨折风险无关;CKD G4和G5患者死亡风险显著增高,竞争风险可能解释上述发现。

要点

  • 髋部骨折后CKD G3-G5患者任何后续非髋部骨折风险略低(HR 0.90),主要非髋部脆性骨折风险未增加。
  • CKD G4和G5患者死亡风险分别为eGFR>60者的1.50倍和2.93倍,竞争风险可能解释骨折风险未增。
  • 临床应重视CKD G4-G5髋部骨折患者的高死亡风险,而非过度担忧后续脆性骨折。

核心结论

  • 髋部骨折后CKD G3-G5患者与eGFR>60 ml/min者相比,主要非髋部脆性骨折风险未增加。
  • CKD G4和G5患者死亡风险显著增高,竞争风险可能解释后续骨折风险未增甚至降低。

研究设计与样本

  • 基于英国临床实践研究数据链(CPRD)的人群队列研究,纳入首次髋部骨折患者。
  • 采用Cox比例风险分析估计CKD分期与后续骨折风险的HR,并计算死因别HR以探索竞争风险。

主要发现

  • CKD G3-G5与任何后续非髋部骨折风险降低相关(HR: 0.90, 95%CI: 0.83-0.97)。
  • CKD G3-G5与后续主要非髋部脆性骨折风险无关。
  • CKD G3-G5与死亡风险增高相关(cs-HR: 1.05, 95%CI: 1.01-1.09)。
  • CKD G4死亡风险cs-HR: 1.50(95%CI: 1.38-1.62),G5死亡风险cs-HR: 2.93(95%CI: 2.48-3.46)。

临床怎么用

  • 对髋部骨折合并CKD G4-G5患者,应优先管理高死亡风险,而非强化后续脆性骨折预防。
  • CKD G3-G5髋部骨折患者主要非髋部脆性骨折风险未增加,骨折预防策略可参考一般人群。

局限性

  • 观察性设计可能存在残余混杂。
  • 死亡作为竞争风险可能掩盖骨折真实风险,需谨慎解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Chronic kidney disease (CKD) is a risk factor for fractures. However, in hip fracture patients, CKD G3-G5 was associated with a higher mortality risk and not associated with a higher risk of subsequent non-hip fractures compared to eGFR > 60 ml/min. The higher mortality risk may, as competing risk, explain our findings. INTRODUCTION: Chronic kidney disease (CKD) is a known risk factor for fragility fractures. Patients aged 50+ with a recent fragility fracture have an increased risk of subsequent fractures. Our aim was to evaluate the association between CKD stages G3-G5 versus estimated glomerular filtration rate (eGFR) > 60 ml/min and the risk of a new non-hip fracture or fragility fracture in patients with a first hip fracture. METHODS: Population-based cohort study using the UK general practices in the Clinical Practice Research Datalink. Associations between CKD stage and first subsequent fracture were determined using Cox proportional hazard analyses to estimate hazard ratios (HRs). To explore the potential competing risk of mortality, cause-specific (cs) HRs for mortality were estimated. RESULTS: CKD G3-G5 was associated with a lower risk of any subsequent non-hip fracture (HR: 0.90, 95%CI: 0.83-0.97), but not with the risk of subsequent major non-hip fragility fracture. CKD G3-G5 was associated with a higher mortality risk (cs-HR: 1.05, 95%CI: 1.01-1.09). Mortality risk was 1.5- to 3-fold higher in patients with CKD G4 (cs-HR: 1.50, 95%CI: 1.38-1.62) and G5 (cs-HR: 2.93, 95%CI: 2.48-3.46) compared to eGFR > 60 ml/min. CONCLUSIONS: The risk of a subsequent major non-hip fragility fractures following hip fracture was not increased in patients with CKD G3-G5 compared to eGFR > 60 ml/min. Mortality risk was higher in both hip fracture and non-hip fracture patients with CKD G4 and G5. The higher mortality risk may, as competing risk, explain our main finding of no increased or even decreased subsequent fracture risk after a hip fracture in patients with CKD G3-G5.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. de Bruin IJA, Wyers CE, Souverein PC, et al. The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK. Osteoporos Int. 2020. PMID: 32266436. doi:10.1007/s00198-020-05351-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。